Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for January 19, 2021

1/19/2021

 
Regulatory Update 
 
The FDA accepted the NDA for finerenone for the treatment of chronic kidney disease in patients with type 2 diabetes, suggesting a PDUFA date of 7/12/2021.
 
The FDA designated ligelizumab a Breakthrough Therapy for the treatment of chronic spontaneous urticaria in patients who have an inadequate response to H1-antihistamine treatment.
 
The FDA granted padeliporfin a Fast Track designation for the treatment of low-grade and unifocal high-grade Upper Tract Urothelial Cancer. 
 
Announced Research Updates
 
Mesoblast announced that in the 30-month, 537 patient, Phase III, DREAM-HF trial, treatment with a single dose of rexlemestrocel-L resulted in a 20.6% incidence of cardiac death, heart attack or stroke compared to 30% incidence with placebo in patients with chronic heart failure with reduced left ventricular ejection fraction, that were receiving optimal oral therapy.
 
Published Research Updates
 
In a 162 patient, Phase II, open-label trial, treatment with olmutinib resulted in an objective response rate of 46.3% in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
 
In the 96-week, 38 patient, Phase III, RESCUE trial, the eyes treated with lenadogen nolparvovec had an improvement in best corrected visual acuity of 10 letters on the ETDRS scale compared to a 9 letter gain in the eyes that received sham injection in patients with Leber Hereditary Optic Neuropathy.
 
In the 12-week, 88 patient, dose-ranging, Phase II STARS trial, 66.7% of patients treated with gaboxadol reduced their Clinical Global Impressions-Improvement scale (CGI-I) score compared to 39.3% with placebo in patients with Angelman syndrome. A post-hoc analysis examined the CGI-I score to determine the number of patients that were very much improved or much improved and found that 32.1% of patients that received gaboxadol once daily reached this threshold compared to 7.1% of placebo patients. There was not a significant improvement compared to placebo with gaboxadol twice daily.
 
In a 48-week, 75 patient, Phase II trial, patients treated with bimagrumab had a 20.5% decrease in total body fat mass compared to a 0.5% decrease with placebo in patients with obesity and type 2 diabetes.
 
In the 52-week, 1,252 patient, Phase III, FINCH 3 trial, the percentage of patients that achieved ACR20 at 24 weeks was 81% with filgotinib 200 mg plus methotrexate and 80% with filgotinib 100 mg plus methotrexate compared to 71% with methotrexate alone in patients with moderate-to-severe rheumatoid arthritis naive to methotrexate. There was no difference between the number of patients that achieved AR20 with filgotinib 200 mg alone compared to methotrexate alone.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.